Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis
Status:
Unknown status
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12
months of treatment will be randomized to continue IFX or to stop IFX and start Azathioprine
(AZA).
Each patient will be followed for 12 months.